BioMarin Pharmaceutical Inc. [BMRN] is following downward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $88.27 after BMRN shares went down by -3.11% during the last trading session. One of the reasons why Healthcare stocks may go bearish is decreased momentum in the press.
BioMarin Pharmaceutical Inc. [NASDAQ:BMRN]: Analyst Rating and Earnings
Its stock price has been found in the range of 62.88 to 100.13. This is compared to its latest closing price of $91.10.
Keep your eyes on this company’s next financial results, which are scheduled to be made public on Thu 20 Feb (In 38 Days).
Fundamental Analysis of BioMarin Pharmaceutical Inc. [BMRN]
Now let’s turn to look at profitability: with a current Operating Margin for BioMarin Pharmaceutical Inc. [BMRN] sitting at -10.60 and its Gross Margin at +76.92, this company’s Net Margin is now -2.70%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -4.08, and its Return on Invested Capital has reached -1.50%. Its Return on Equity is -2.67, and its Return on Assets is -1.68. These metrics suggest that this BioMarin Pharmaceutical Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, BioMarin Pharmaceutical Inc. [BMRN] has generated a Total Debt to Total Equity ratio of 27.98. Similarly, its Total Debt to Total Capital is 21.86, while its Total Debt to Total Assets stands at 18.50. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -3.63, and its Long-Term Debt to Total Capital is 27.98.
What about valuation? This company’s Enterprise Value to EBITDA is -234.92. The Enterprise Value to Sales for this firm is now 9.32, and its Total Debt to Enterprise Value stands at 0.06. BioMarin Pharmaceutical Inc. [BMRN] has a Price to Book Ratio of 5.11, a Price to Cash Flow Ratio of 746.08.
Shifting the focus to workforce efficiency, BioMarin Pharmaceutical Inc. [BMRN] earns $525,524 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 4.96 and its Total Asset Turnover is 0.33. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.92 and its Current Ratio is 3.93. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
BioMarin Pharmaceutical Inc. [BMRN] has 179.29M shares outstanding, amounting to a total market cap of $15.83B. Its stock price has been found in the range of 62.88 to 100.13. At its current price, it has moved down by -11.84% from its 52-week high, and it has moved up 40.38% from its 52-week low.
This stock’s Beta value is currently 1.39, which indicates that it is 3.40% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 64.26. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is BioMarin Pharmaceutical Inc. [BMRN] a Reliable Buy?
Shares of BioMarin Pharmaceutical Inc. [BMRN], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.